Skip to main content
. 2014 Aug 29;9(8):e106422. doi: 10.1371/journal.pone.0106422

Figure 7. Some mice treated with Ad/VNA-BoNTA develop blocking antibodies.

Figure 7

Serum from mice treated with Ad/VNA-BoNTA or Ad/VNA-control was collected monthly from weeks 2 through 18 post-treatment and VNA levels were assessed (data shown in Figure 6). A–C. Development of blocking Abs was investigated in the three Ad/VNA-BoNTA mice with low serum VNA levels (Figure 6A; square, circle and diamond symbols). The presence of blocking Abs was assayed by measuring the potency of mouse serum, 1∶100, to inhibit the binding of serially diluted recombinant VNA-BoNTA (Trx/H7/B5/ABP) to BoNT/A1. The presence of blocking Abs shifts the curve to the left. Each box represents sera collected from the same mice at the indicated times post-treatment with Ad/VNA-BoNTA. D. VNA-BoNTA blocking assays were performed as above in A–C employing serum from mice 18 weeks following treatment with Ad/VNA-control to detect VNA cross-specific blocking Abs elicited by expression of the control VNA. The serum source was the terminal bleed of the five mice in Figure 6B.